Superworth

Oramed Pharmaceuticals price to book ratio ORMP

Market value divided by the book value of the company's net assets, since 2012.

Today, Oct 23, 2026
0.5×
10-year median
2.1×
Against its 10-year history
4th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.5× to 13.7×
Peer median
1.6×

Oramed Pharmaceuticals' price to book ratio is 0.5× as of Oct 23, 2026.

That is below its ten-year median of 2.1×, lower than on 96% of days in the last ten years.

Over that time it ranged from 0.5× in Nov 2025 to 13.7× in Nov 2021.

The median for 10 large drugmakers of a similar size is 1.6×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.5×0.5×0.9×
20250.6×0.5×0.7×
20240.6×0.5×0.9×
20230.6×0.5×2.9×
20223.1×0.9×4.1×
20214.7×3.2×13.7×
20203.1×1.7×5.8×
20194.6×1.9×4.8×
20181.7×1.7×6.6×
20176.7×3.2×7.5×
20163.1×2.5×4.2×
20154.0×1.8×4.5×
20142.2×2.2×30.8×
201312.7×4.6×15.2×
20124.6×4.6×12.1×

Against its peers

Companies in Drug Manufacturers - General nearest Oramed Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
ORMPOramed Pharmaceuticals0.5×
NATRNatures Sunshine Products1.3×
LFVNLifevantage2.2×
SPROSpero Therapeutics1.5×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
ATNMActinium Pharmaceuticals1.6×
COLLCollegium Pharmaceutical2.4×
Peer median1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Oramed Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.